OSLO, Norway, Aug 15, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, will announce its second quarter and first half year 2018 results on Thursday, 23 August 2018. A presentation by Targovax's management to investors, analysts and the press will take place in Oslo at 10:00 CET.
The results report and the presentation will be available at www.targovax.com in the Investors section from 07:00 CET.
The presentation will take place at 10:00 CET at:
For further information, please contact:
Renate Birkeli, Investor Relations
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
This information was brought to you by Cision http://news.cision.com